Brind.
  1. TD Cowen provided analyst estimates for US sales while the FDA continues to regulate drug approval in the US market.

Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.

1 report, 0 independent Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.

Who's involved

What this event is mainly about
Organon & Co.TD Cowen

Keep exploring

Part of

TD Cowen provided analyst estimates for US sales while the FDA continues to regulate drug approval in the US market. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet